Glenmark Pharmaceuticals announced the launch of Fingolimod Capsules, 0.5 mg, the generic version of Gilenya®1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
Glenmark's current portfolio consists of 176 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA.